tirzepatide clinical trial enrollment on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 Tirzepatide: First Approval | Drugs
Description
When we identify and correct root causes (hormones, gut, nutrients, sleep), fat loss becomes easier and more sustainable
Frequency: one subcutaneous injection each week
seasonal pattern
However, it is not recommended to be taken on an empty stomach
